Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
Expert Opin Pharmacother
; 11(12): 1971-82, 2010 08.
Article
en En
| MEDLINE
| ID: mdl-20569086
ABSTRACT
AIM:
To evaluate the effects of 1-year treatment with orlistat compared with placebo on different inflammatory parameters in type 2 obese diabetic patients. MATERIALS ANDMETHODS:
Two hundred and fifty-four type 2 diabetic patients were randomized to take orlistat 120 mg three times a day or placebo for 12 months. We evaluated at baseline and after 3, 6, 9 and 12 months leptin, tumor necrosis factor (TNF)-alpha, adiponectin (ADN), vaspin and high-sensitivity C-reactive protein (HS-CRP), body weight, waist circumference, body mass index (BMI), lipid profile, glycemic profile, fasting plasma insulin (FPI) and homeostasis model assessment insulin resistance index (HOMA-IR).RESULTS:
Regarding inflammatory parameters, there was a significant improvement of ADN and TNF-alpha, and a faster decrease of leptin and HS-CRP in the orlistat group compared with the control group. We also recorded a significant reduction of body weight and BMI with orlistat, but not with placebo. A faster improvement of glycemic profile and FPI was obtained with orlistat compared with the controls. Also, there was a significant reduction of lipid profile with orlistat, not reached with placebo.CONCLUSIONS:
Orlistat was more effective than placebo in ameliorating inflammatory parameters such as ADN and TNF-alpha, and anthropometric parameters.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Mediadores de Inflamación
/
Fármacos Antiobesidad
/
Diabetes Mellitus Tipo 2
/
Hipoglucemiantes
/
Lactonas
/
Obesidad
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
País/Región como asunto:
Europa
Idioma:
En
Revista:
Expert Opin Pharmacother
Asunto de la revista:
FARMACOLOGIA
Año:
2010
Tipo del documento:
Article
País de afiliación:
Italia